- Home
- CWEN vs TVTX Comparison
CWEN vs TVTX Comparison
Compare CWEN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- TVTX
- Stock Information
- Founded
- CWEN 2012
- TVTX 2008
- Country
- CWEN United States
- TVTX United States
- Employees
- CWEN N/A
- TVTX N/A
- Industry
- CWEN Electric Utilities: Central
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- TVTX Health Care
- Exchange
- CWEN Nasdaq
- TVTX Nasdaq
- Market Cap
- CWEN 3.8B
- TVTX 3.1B
- IPO Year
- CWEN 2013
- TVTX N/A
- Fundamental
- Price
- CWEN $35.58
- TVTX $35.36
- Analyst Decision
- CWEN Buy
- TVTX Strong Buy
- Analyst Count
- CWEN 6
- TVTX 15
- Target Price
- CWEN $37.17
- TVTX $37.21
- AVG Volume (30 Days)
- CWEN 1.3M
- TVTX 2.2M
- Earning Date
- CWEN 11-04-2025
- TVTX 10-30-2025
- Dividend Yield
- CWEN 4.88%
- TVTX N/A
- EPS Growth
- CWEN 125.75
- TVTX N/A
- EPS
- CWEN 2.34
- TVTX N/A
- Revenue
- CWEN $1,375,000,000.00
- TVTX $435,826,000.00
- Revenue This Year
- CWEN N/A
- TVTX $108.68
- Revenue Next Year
- CWEN N/A
- TVTX $40.23
- P/E Ratio
- CWEN $15.17
- TVTX N/A
- Revenue Growth
- CWEN 0.81
- TVTX 114.22
- 52 Week Low
- CWEN $24.40
- TVTX $12.91
- 52 Week High
- CWEN $36.89
- TVTX $36.87
- Technical
- Relative Strength Index (RSI)
- CWEN 67.08
- TVTX 62.83
- Support Level
- CWEN $35.81
- TVTX $34.18
- Resistance Level
- CWEN $36.89
- TVTX $36.87
- Average True Range (ATR)
- CWEN 0.93
- TVTX 1.95
- MACD
- CWEN -0.01
- TVTX -0.21
- Stochastic Oscillator
- CWEN 71.62
- TVTX 73.11
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.